Genethera Stock Today
| GTHR Stock | USD 0.0001 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 44
|
GeneThera is selling at 1.0E-4 as of the 26th of November 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 1.0E-4. GeneThera has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for GeneThera are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. The company has 35.33 M outstanding shares. More on GeneThera
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
GeneThera Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
GeneThera [GTHR] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 533.53 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GeneThera's market, we take the total number of its shares issued and multiply it by GeneThera's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. GeneThera conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 35.33 M outstanding shares.
GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations.
Check GeneThera Probability Of Bankruptcy
Ownership AllocationGeneThera has a total of 35.33 Million outstanding shares. GeneThera retains 17.99 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GeneThera Ownership Details
GeneThera Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in GeneThera without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
GeneThera Corporate Executives
Elected by the shareholders, the GeneThera's board of directors comprises two types of representatives: GeneThera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneThera. The board's role is to monitor GeneThera's management team and ensure that shareholders' interests are well served. GeneThera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneThera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tannya Irizarry | Chief Admin. Officer, Interim CFO, Interim Principal Accounting Officer and Secretary | Profile |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.